LibGuides: COVID-19 Vaccines: Johnson &amp; Johnson Vaccine

JOHNSON & JOHNSON (JENSSEN) COVID-19 VACCINE

April 23, 2021

FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review

Agencies Underscore Confidence in Vaccine’s Safety and Effectiveness Following Data Assessment; Available Data Suggest Potential Blood Clots Are Very Rare Events

CDC - Johnson & Johnson’s Janssen COVID-19 Vaccine Overview and Safety
General Information, who should and should not get vaccinated, possible side effects.
FDA Janssen COVID-19 Vaccine Factsheet
On February 27, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
MedlinePlus - Janssen Vaccine
Details, including risks, benefits and possible side effects.

Safety Data Summary

In clinical trials, side effects were common within 7 days of getting vaccinated but were mostly mild to moderate.
Side effects were more common in people 18–59 years old compared to people 60 years and older.
CDC will continue to provide updates as we learn more about the safety of the J&J/Janssen vaccine in real-world conditions.

SOURCE: CDC - https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html (April 15, 2021)

How Well the Vaccine Works

The J&J/Janssen vaccine was 66.3% effective in clinical trials (efficacy) at preventing laboratory-confirmed COVID-19 illness in people who had no evidence of prior infection 2 weeks after receiving the vaccine. People had the most protection 2 weeks after getting vaccinated.
The vaccine had high efficacy at preventing hospitalization and death in people who did get sick. No one who got COVID-19 at least 4 weeks after receiving the J&J/Janssen vaccine had to be hospitalized.
Early evidence suggests that the J&J/Janssen vaccine might provide protection against asymptomatic infection, which is when a person is infected by the virus that causes COVID-19 but does not get sick.
CDC will continue to provide updates as we learn more about how well the J&J/Janssen vaccine works in real-world conditions.

SOURCE: CDC - https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html (April 15, 2021)

Clinical Trial Demographic Information

Clinical trials for the J&J/Janssen vaccine included people from the following racial and ethnic categories:

62.1% White
17.2% Black or African American
8.3% American Indian or Alaska Native
5.4% Multiple races
3.5% Asian
0.3% Native Hawaiian or other Pacific Islander

Ethnicity:

45.1% Hispanic or Latino
52.4% Not Hispanic or Latino
2.5% Unknown

Sex breakdown:

55.5% Male
44.5% Female
<0.1% Undifferentiated or unknown sex

Age breakdown:

66.5% 18–59 years
33.5% 60 years and older
- 19.6% 65 years and older
- 3.5% 75 years and older

SOURCE: CDC - https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html (April 15, 2021)

More Information